| Jeffery W Carroll, CRNA | |
|
2101 Pease St, Harlingen, TX 78550-8307 | |
| (956) 389-1100 | |
| (956) 389-1800 |
| Full Name | Jeffery W Carroll |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 12 Years |
| Location | 2101 Pease St, Harlingen, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295077279 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 631332 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christus Spohn Hospital Corpus Christi | Corpus christi, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergenchealth Pllc | 1355606641 | 585 |
| Opcare | 8820462518 | 8 |
News Archive
Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.
Family Research Council (FRC) President Tony Perkins released the following statement in response to the Supreme Court issuing a temporary injunction in the case involving the Little Sisters of the Poor against the U.S. Department of Health and Human Services (HHS) mandate.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.
If a blood count is abnormal, the medical laboratory scientist (MLS) has to manually perform a differential blood count analysis. This costs time and money. The computer-assisted blood cell analysis system HemaCAM by the company Horn has recently been launched on the market and does just this. At the MEDICA 2010 trade fair, which is being held from November 17 to 20 in Düsseldorf, Germany, scientists from the Fraunhofer Institute for Integrated Circuits IIS will be presenting this intelligent microscopy system at joint stand F05 in hall 10.
› Verified 9 days ago
| Entity Name | Harlingen Anesthesia Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093727455 PECOS PAC ID: 5294637112 Enrollment ID: O20040122000244 |
News Archive
Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.
Family Research Council (FRC) President Tony Perkins released the following statement in response to the Supreme Court issuing a temporary injunction in the case involving the Little Sisters of the Poor against the U.S. Department of Health and Human Services (HHS) mandate.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.
If a blood count is abnormal, the medical laboratory scientist (MLS) has to manually perform a differential blood count analysis. This costs time and money. The computer-assisted blood cell analysis system HemaCAM by the company Horn has recently been launched on the market and does just this. At the MEDICA 2010 trade fair, which is being held from November 17 to 20 in Düsseldorf, Germany, scientists from the Fraunhofer Institute for Integrated Circuits IIS will be presenting this intelligent microscopy system at joint stand F05 in hall 10.
› Verified 9 days ago
| Entity Name | Emergenchealth Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467970897 PECOS PAC ID: 1355606641 Enrollment ID: O20180608000439 |
News Archive
Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.
Family Research Council (FRC) President Tony Perkins released the following statement in response to the Supreme Court issuing a temporary injunction in the case involving the Little Sisters of the Poor against the U.S. Department of Health and Human Services (HHS) mandate.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.
If a blood count is abnormal, the medical laboratory scientist (MLS) has to manually perform a differential blood count analysis. This costs time and money. The computer-assisted blood cell analysis system HemaCAM by the company Horn has recently been launched on the market and does just this. At the MEDICA 2010 trade fair, which is being held from November 17 to 20 in Düsseldorf, Germany, scientists from the Fraunhofer Institute for Integrated Circuits IIS will be presenting this intelligent microscopy system at joint stand F05 in hall 10.
› Verified 9 days ago
| Entity Name | Opcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689265431 PECOS PAC ID: 8820462518 Enrollment ID: O20230320002742 |
News Archive
Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.
Family Research Council (FRC) President Tony Perkins released the following statement in response to the Supreme Court issuing a temporary injunction in the case involving the Little Sisters of the Poor against the U.S. Department of Health and Human Services (HHS) mandate.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.
If a blood count is abnormal, the medical laboratory scientist (MLS) has to manually perform a differential blood count analysis. This costs time and money. The computer-assisted blood cell analysis system HemaCAM by the company Horn has recently been launched on the market and does just this. At the MEDICA 2010 trade fair, which is being held from November 17 to 20 in Düsseldorf, Germany, scientists from the Fraunhofer Institute for Integrated Circuits IIS will be presenting this intelligent microscopy system at joint stand F05 in hall 10.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffery W Carroll, CRNA 1702 N Ed Carey Dr, Harlingen, TX 78550-8202 Ph: (956) 423-4589 | Jeffery W Carroll, CRNA 2101 Pease St, Harlingen, TX 78550-8307 Ph: (956) 389-1100 |
News Archive
Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.
Family Research Council (FRC) President Tony Perkins released the following statement in response to the Supreme Court issuing a temporary injunction in the case involving the Little Sisters of the Poor against the U.S. Department of Health and Human Services (HHS) mandate.
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.
If a blood count is abnormal, the medical laboratory scientist (MLS) has to manually perform a differential blood count analysis. This costs time and money. The computer-assisted blood cell analysis system HemaCAM by the company Horn has recently been launched on the market and does just this. At the MEDICA 2010 trade fair, which is being held from November 17 to 20 in Düsseldorf, Germany, scientists from the Fraunhofer Institute for Integrated Circuits IIS will be presenting this intelligent microscopy system at joint stand F05 in hall 10.
› Verified 9 days ago
Mr. Jose L Garcia Iii, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2101 Pease St, Harlingen, TX 78550 Phone: 956-867-2530 | |
Helen Delores Padgett, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2101 Pease St, Harlingen, TX 78550 Phone: 956-389-1100 Fax: 956-389-1800 | |
Mr. Rene Lee Acosta, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3202 Tucker Rd, Harlingen, TX 78552 Phone: 956-536-7363 | |
Robin Melinda Woodard, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2101 Pease St, Harlingen, TX 78550 Phone: 956-389-1100 Fax: 956-389-1800 | |
Gonzalo Flores, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2101 Pease St, Harlingen, TX 78550 Phone: 956-389-1100 Fax: 956-389-1800 | |
Perla C Rufo, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2101 Pease St, Harlingen, TX 78550 Phone: 956-389-1100 Fax: 956-389-1800 | |
Jessica L Appel, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2101 Pease St, Harlingen, TX 78550 Phone: 956-389-1100 Fax: 956-389-1800 |